- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05250011
Observation of Italian Patients With Heart Failure Being Treated With Dapagliflozin in Clinical Practice (EVOLUTION-HF)
Early Treatment of Heart Failure: a Non-Interventional Observational Study of Italian Patients With Heart Failure and Initiated on Dapagliflozin
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Heart failure (HF) is a significant burden for public health, affecting more than 63 million people worldwide and expected to increase as the population ages; in Italy, the estimated prevalence of HF is 1-3% and the incidence rate 2-5 cases per 1000 persons per year. Despite advancements in treatment, a HF diagnosis still leads to significant morbidity and mortality and impacts on patients' quality of life (QoL). Dapagliflozin is the first in a novel class of glucose-lowering agents known as sodium-glucose co-transporter-2 (SGLT2) inhibitors, approved for the treatment of Heart Failure with reduced Ejection Fraction (HFrEF). As with all new drugs introduced into clinical practice, there is a strong scientific interest in producing evidence from observational studies regarding the use of dapagliflozin for the treatment of HFrEF in real-world settings with detailed clinical data on heart failure symptoms, outcomes, and health-related QoL.
The overall aim of this observational study is to describe the characteristics of patients in Italy initiating dapagliflozin for the treatment of HFrEF and to provide early insights into real-world dapagliflozin treatment patterns (primary objectives) as well as patient-reported outcomes including quality of life (secondary objectives).
This study is part of a multicountry study programme, including similar studies that will be conducted in other countries with similar objectives. Data from each of the individual studies may be combined in a pooled analysis.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Napoli, Italy, 80131
- Research Site
-
-
BS
-
Brescia, BS, Italy, 25123
- Research Site
-
-
CZ
-
Catanzaro, CZ, Italy, 88100
- Research Site
-
-
FG
-
Foggia, FG, Italy, 71122
- Research Site
-
-
FI
-
Firenze, FI, Italy, 50100
- Research Site
-
-
GE
-
Genova, GE, Italy, 16132
- Research Site
-
-
MB
-
Monza, MB, Italy, 20900
- Research Site
-
-
MI
-
Milano, MI, Italy, 20122
- Research Site
-
-
RM
-
Roma, RM, Italy, 00163
- Research Site
-
Roma, RM, Italy, 00189
- Research Site
-
-
TS
-
Trieste, TS, Italy, 34125
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Patients prescribed with dapagliflozin for Heart Failure with reduced Ejection Fraction (HFrEF) according to the approved indication will be eligible for enrollment from both outpatient and inpatient settings.
The decision to treat a patient with dapagliflozin must be made prior to the decision to enroll the patient. In order to help ensuring this, participants can be enrolled only if they started treatment with dapagliflozin at least 14 days before the enrollment visit, regardless of the treatment being discontinued or suspended in the time between first dapagliflozin prescription and enrollment visit.
It is expected that 250 participants will be consecutively enrolled in about 11 centres (approximately 23 participants per each study site).
Description
Inclusion Criteria:
- Age equal or above 18 years old at the initiation of treatment with dapagliflozin
- Participant received/receiving treatment with dapagliflozin for Heart Failure with reduced Ejection Fraction (HFrEF) in accordance with the approved local dapagliflozin product label, i.e. with an ejection fraction of 40 percent or less
- Signed and dated informed cconsent obtained prior to enrollment into the study
Exclusion Criteria:
- Participant is enrolled less than 14 days or more than 45 days following the initiation of treatment with dapagliflozin
- Prior treatment with dapagliflozin or other treatment with a medicine of the same drug class (sodium-glucose co-transporter-2 - or SGLT2 - inhibitors)
- Initiation of dapagliflozin outside of the approved local dapagliflozin product label for HFrEF
- Diagnosis of Type 1 Diabetes
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Single-cohort
Patients initiated on dapagliflozin according to the approved indication for heart failure with reduced ejection fraction (HFrEF) and current medical practice
|
Dapagliflozin, prescribed as per approved indication and current medical practice.
Participants will not receive any experimental disease management intervention or experimental treatment as a consequence of their participation in the study.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Baseline characteristics of participants
Time Frame: Baseline (enrollment)
|
Demographic and clinical characteristics at baseline of study participants
|
Baseline (enrollment)
|
|
Dapagliflozin treatment pattern
Time Frame: 12 months from prescription of dapagliflozin
|
Treatment discontinuation events for dapagliflozin
|
12 months from prescription of dapagliflozin
|
|
Other medications treatment patterns
Time Frame: 12 months from prescription of dapagliflozin
|
Treatment change events for other medications for heart failure and glucose-lowering medications
|
12 months from prescription of dapagliflozin
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient Reported Outcome: Kansas City Cardiomyopathy Questionnaire (KCCQ)
Time Frame: Baseline (enrollment), Follow-up (3, 6, 12 months after treatment initiation)
|
Health-Related Quality of Life: assessment of heart failure symptoms and their impact in terms of physical limitation and quality of life, as captured by the Kansas City Cardiomyopathy Questionnaire (KCCQ).
The KCCQ is scored on a scale from 0 to 100, with higher scores indicating higher quality of life.
|
Baseline (enrollment), Follow-up (3, 6, 12 months after treatment initiation)
|
|
Patient Reported Outcome: Medication Adherence Report Scale (MARS-5)
Time Frame: Baseline (enrollment), Follow-up (3, 6, 12 months after treatment initiation)
|
Assessment of medication adherence to heart failure treatments, as captured by the five-items version of the Medication Adherence Report Scale (MARS-5).
The MARS-5 is scored on a scale from 0 to 25, with higher scores indicating better treatment compliance.
|
Baseline (enrollment), Follow-up (3, 6, 12 months after treatment initiation)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Marco Metra, MD, UOC Cardiologia, Spedali Civili di Brescia
- Principal Investigator: Maurizio Volterrani, MD, UO Riabilitazione Cardiologica, IRCCS San Raffaele, Roma
- Principal Investigator: Pasquale Perrone Filardi, MD, UOC Cardiologia emodinamica e UTIC, Azienda Ospedaliera Universitaria "Federico II", Napoli
- Principal Investigator: Massimo Iacoviello, MD, Unità di Cardiologia, Azienda Ospedaliero Universitaria Ospedali Riuniti, Foggia
- Principal Investigator: Pietro Ameri, MD, UO Clinica Malattie Apparato Cardiovascolare e UTIC, IRCCS Ospedale Policlinico San Martino, Genova
- Principal Investigator: Andrea Ungar, MD, Geriatria UTIG, Azienda Ospedaliero Universitaria Careggi, Firenze
- Principal Investigator: Ciro Indolfi, MD, UO Cardiologia-Emodinamica-UTIC, Azienda Ospedaliero Universitaria Mater Domini, Catanzaro
- Principal Investigator: Massimo Volpe, MD, UOC Cardiologia, Azienda Ospedaliera Sant'Andrea, Roma
- Principal Investigator: Andrea Mortara, MD, Dipartimento di Cardiologia, Policlinico di Monza, Monza
- Principal Investigator: Stefano Carugo, MD, Unità di Cardiologia, IRCCS Ca' Granda - Ospedale Maggiore - Policlinico, Milano
- Principal Investigator: Andrea Di Lenarda, MD, Cardiologia, Azienda Sanitaria Universitaria Giuliano Isontina, Trieste
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D1699R00030
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca sponsored studies via the request portal.
All request will be evaluated as per the AZ disclosure commitment:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD Sharing Time Frame
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD Sharing Access Criteria
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.